Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

Data ReadoutINBRX-106Neutral

AI Analysis

Summary

Inhibrx will host a webcast to present primary endpoint results from its Phase 2 first-line HNSCC study of INBRX-106. The announcement indicates upcoming data readout with no outcome details disclosed.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Primary endpoint results for Phase 2 first-line HNSCC study

Importance:6/10

Sentiment:

0.00

oncologyHNSCCPhase 2data readoutwebcast presentation

Related Companies

$INBX

Read the original article

Published by yahoo_finance on September 4, 2026 8:00 PM

Read Original